BPI-9016

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBPI-9016
Drug Alias NameBPI-9016BPI-9016M
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsAXL receptor tyrosine kinase inhibitors
TargetsAXL receptor tyrosine kinaseHepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBetta Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBetta Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A